North America HIV Injection Market

North America HIV Injection Market Size, Share & Trends Analysis Report By Distribution Channel (Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others), By Country and Growth Forecast, 2023 - 2030

Report Id: KBV-21372 Publication Date: March-2024 Number of Pages: 91
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Analysis of Market Size & Trends

The North America HIV Injection Market would witness market growth of 16.9% CAGR during the forecast period (2023-2030).

The US market dominated the North America HIV Injection Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $905.8 Million by 2029. The Canada market is experiencing a CAGR of 19.6% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 18.5% during (2023 - 2030).

HIV (Human Immunodeficiency Virus) is a pathogen that targets the immune system's CD4 cells (T cells), which are crucial for defending against infections. HIV reduces the number of CD4 cells in the body, increasing the risk of infection-related cancers and infections if left untreated. A progressive depletion of these cells by HIV may render the body incapable of combating infections and diseases.

HIV is transmitted through contact with specific bodily fluids from an infected individual, including blood, sperm, vaginal fluids, rectal fluids, and breast milk. Sexual contact without protection, sharing needles or syringes with an infected person, and transmission from mother to child during childbirth or breastfeeding are the most prevalent modes of HIV transmission.

A significant public health concern is the increasing prevalence of HIV in North America, especially in certain populations and geographic regions. An increasing prevalence of HIV is also being observed in Canada. The Government of Canada reports that with 1,472 new cases, representing an 11.3% increase, the national rate of new HIV diagnoses for 2021 stood at 3.8 per 100,000 population. Hence, all of these factors will aid in the market's growth.

Free Valuable Insights: The HIV Injection Market is Predict to reach USD 2.8 Billion by 2030, at a CAGR of 17.6%

Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

List of Key Companies Profiled

  • GlaxoSmithKline PLC (GSK)
  • Gilead Sciences, Inc.
  • ImmunityBio, Inc.
  • F.Hoffmann-La Roche Ltd.
  • Theratechnologies Inc.
  • Viriom, Inc.
  • AbbVie, Inc.
  • Brii Biosciences Limited
  • Shionogi & Co., Ltd.
  • Boehringer Ingelheim International GmbH

North America HIV Injection Market Report Segmentation

By Distribution Channel

  • Hospital Pharmacy
  • Drugs Stores & Retail Pharmacies
  • Others

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo